Back to Search Start Over

LARS™ in ACL reconstruction: evaluation of 60 cases with 5-year minimum follow-up.

Authors :
Bugelli G
Dell'Osso G
Ascione F
Gori E
Bottai V
Giannotti S
Source :
Musculoskeletal surgery [Musculoskelet Surg] 2018 Apr; Vol. 102 (1), pp. 57-62. Date of Electronic Publication: 2017 Sep 05.
Publication Year :
2018

Abstract

Purpose: The injury of anterior cruciate ligament (ACL) causes joint instability and, in the absence of adequate treatment, progressive joint deterioration, meniscal lesions and development of post-traumatic osteoarthritis.<br />Methods: The purpose of this study was to evaluate the clinical, functional and radiographic outcomes and complications in a consecutive case series of 60 patients with minimum follow-up of 5 years who underwent an arthroscopic surgery for ACL reconstruction using LARS™ ligament. Patients with concomitant meniscal or chondral lesions in the same knee were excluded.<br />Results: The subjective evaluation of the patients involved in the study (Lysholm score, IKDC score and Tegner activity level scale) shows good/excellent results. The range of movement is optimal in most patients, and pain symptoms are considered mild. A total of 31.25% of the patients did not change their lifestyle that they had before the injury. None of the patients underwent resurgery in the same knee. In 85.4% of cases, X-ray images showed no signs of osteoarthritis after ACL reconstruction.<br />Conclusions: Comparable with other series showed in the literature, this study assesses that the use of LARS™ in reconstruction of ACL is an excellent option for treating >40-year-old patients requesting rapid return to daily activities/sports also at the first surgery. By restoring knee stability, articular degeneration at short and medium follow-up was avoided.

Details

Language :
English
ISSN :
2035-5114
Volume :
102
Issue :
1
Database :
MEDLINE
Journal :
Musculoskeletal surgery
Publication Type :
Academic Journal
Accession number :
28875272
Full Text :
https://doi.org/10.1007/s12306-017-0499-3